Phase 2 N=50 Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant
Type 2 Diabetes
Primary: Insulin Secretion — 5; 29 % increase of Ins30
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=184 NOURISH: Nourishing Our Understanding of Role Modeling to Improve Support and Health
Pediatric Obesity
Primary: Child BMI — 98.47; 97.86; 98.19; 97.86 percentile — p=.008
N/A N=398 Life 2: Improving Fitness and Function in Elders
Aging · Mobility Limitations
Primary: Usual Gait Speed — 1.03; 1.03 meters/second
Phase 2 N=38 Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
Diabetic Foot Infections
Primary: Clinical Success (in ITT Population) — 95.7 percentage of participants
Phase 2 N=17 Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Primary: Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria — 0…
N/A N=253 Patient-Centered Adherence Intervention After Acute Coronary Syndrome (ACS) Hospitalization
Acute Coronary Syndrome
Primary: Adherence to Cardioprotective Medications (Clopidogrel, Statins, Beta Blockers, ACE-inhibitor/ARB) — 89.3; 73.9 percentage of participants — p=0.003
Phase 1 N=4 Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites
Parkinson Disease
Primary: Maximum Plasma Concentration (Cmax) — 482.98 ng-eq/mL
Phase 1 N=140 A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers
Healthy
Primary: Number of Participants With Injection Site Reactions Following Either Vaccine Dose Worst Severity Reported — 25; 25; 24; 21 participants
Phase 4 N=674 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Hepatitis B
Primary: Number of Subjects Seroprotected for Anti- Hepatitis B Surface Antigen (Anti-HBs) Antibodies — 285; 155 Participants
Phase 2 N=12 Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients
Kidney Failure
Primary: Net Iron Delivery From SFP Via the Dialysate — 692 microgram
N/A N=68 Walking Skill Training Program Effects in Patients With Total Hip Arthroplasty
Arthroplasty, Replacement, Hip · Exercise Therapy
Primary: 6 Minutes Walk Test (6MWT) — 513; 462; 535; 483 meters
N/A N=5,123 Proactive Tobacco Treatment for Veterans
Smoking Cessation · Smoking Tobacco
Primary: Self-reported, Smoking Abstinence Rate: 6-month Prolonged Abstinence — 10.9; 13.5 percentage of participants — p=.02
N/A N=132 Modification in Complementary Food Composition to Improve the Status of Iron and Fatty Acids in Infants.
Iron Status · Fatty Acid Status
Primary: Sum of Omega-3 Fatty Acid Pattern in Plasma — 2.66; 3.02 percent of total fatty acids
Phase 3 N=302 Enhancing Fitness in Older Pre-diabetic Veterans
Impaired Glucose Tolerance · Obesity · Diabetes
Primary: Fasting Insulin — 10.26; 10.39 uIU/ml
N/A N=212 Patient and Provider Outcomes of E-Learning Training in Collaborative Assessment and Management of Suicidality
Suicide
Primary: Provider Self-efficacy and Beliefs About Suicidality — 45.6; 44.9; 43.0 units on a scale — p=<0.01